Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04319276 · ClinicalTrials.gov registry record · Phase 1
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
A Phase 1 study of Glioblastoma, sponsored by Medical College of Wisconsin.
- Active
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT04319276 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by Medical College of Wisconsin. The registered enrollment target is 26 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04319276, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by Medical College of Wisconsin.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).
Conditions Studied
Interventions
- DRUG Gallium maltolate (500 mg)
- DRUG Gallium maltolate (1,000 mg)
- DRUG Gallium maltolate (1,500 mg)
- DRUG Gallium maltolate (2,000 mg)
- DRUG Gallium maltolate (2,500 mg)
Study Locations (1)
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04319276
The ClinicalTrials.gov registry entry for NCT04319276 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (76% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Gallium maltolate (500 mg) is the first listed.
NCT04319276 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04319276 about?
NCT04319276 is a clinical study titled "Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma". This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).
What is the current status of trial NCT04319276?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2022-11-11. Estimated completion is 2027-03-01.
What conditions does trial NCT04319276 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04319276?
The interventions under investigation include: Gallium maltolate (500 mg) (DRUG), Gallium maltolate (1,000 mg) (DRUG), Gallium maltolate (1,500 mg) (DRUG), Gallium maltolate (2,000 mg) (DRUG), Gallium maltolate (2,500 mg) (DRUG).
Who is sponsoring clinical trial NCT04319276?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04319276 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.